These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 24377908

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 3. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sirolimus in pediatric renal transplantation.
    Kasap B.
    Pediatr Transplant; 2011 Nov; 15(7):673-85. PubMed ID: 22004542
    [Abstract] [Full Text] [Related]

  • 8. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T, Argudo A, Peña-Cala MC.
    Transplant Proc; 2011 Nov; 43(6):2216-9. PubMed ID: 21839237
    [Abstract] [Full Text] [Related]

  • 9. mTOR inhibitors in pediatric kidney transplantation.
    Pape L, Ahlenstiel T.
    Pediatr Nephrol; 2014 Jul; 29(7):1119-29. PubMed ID: 23740036
    [Abstract] [Full Text] [Related]

  • 10. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract] [Full Text] [Related]

  • 11. Treatment with everolimus is associated with a procoagulant state.
    Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [Abstract] [Full Text] [Related]

  • 12. [Everolimus and azoospermia, a causal relationship? About one case in a renal transplant patient].
    Wetzstein M, Weestel PF, Choukroun G.
    Nephrol Ther; 2014 Feb; 10(1):44-5. PubMed ID: 24374233
    [Abstract] [Full Text] [Related]

  • 13. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
    Nashan B.
    Clin Transplant; 2013 Feb; 27 Suppl 25():16-29. PubMed ID: 23909498
    [Abstract] [Full Text] [Related]

  • 14. mTOR Inhibition and Kidney Diseases.
    Ma MKM, Yung S, Chan TM.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [Abstract] [Full Text] [Related]

  • 15. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 16. A drug safety evaluation of everolimus in kidney transplantation.
    Holdaas H, Midtvedt K, Åsberg A.
    Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
    [Abstract] [Full Text] [Related]

  • 17. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F.
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [Abstract] [Full Text] [Related]

  • 18. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S, Baroletti SA.
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [Abstract] [Full Text] [Related]

  • 19. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 20. Can mTOR inhibitors reduce the risk of late kidney allograft failure?
    Ponticelli C.
    Transpl Int; 2008 Jan; 21(1):2-10. PubMed ID: 17635837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.